Leenhardt L, et al. - A sum of 404 individuals were analyzed to assess recombinant human thyrotropin (rhTSH) vs thyroid hormone withdrawal (THW) while preparing for radioactive iodine (RAI) concerning the disease status at the first evaluation in subjects with nodal metastases (N1 DTC). They observed comparable pathological characteristics and originally administrated RAI activities (3.27 ± 1.00 GBq) between the 2 groups. They did not find disease-free rate inferior in the rhTSH group (75.1%) as compared to the THW group (71.9%). Achievement of complete response was obtained at the last evaluation (29.7 ± 20.7 months for rhTSH; 36.7 ± 23.8 months for THW) among 83.5% (rhTSH) and 81.5% (THW) of subjects.